| abstract |
(57) [Summary]nThe present invention describes novel therapeutic agents for movement disorders including tardive dyskinesia and tardive dystonia, tic disorders, Tourette syndrome and blepharospasm and other focal dystonias. The therapeutic agent of the present invention utilizes an agent that simultaneously acts as an NMDA-type glutamate receptor antagonist. Furthermore, the therapeutic agent of the present invention utilizes an agent that simultaneously acts as an NMDA-type glutamate receptor antagonist and a GABA-A receptor agonist. Preferably, these two activities are characteristic of a single agent, such as acamprosate. Alternatively, separate agents having these activities can be combined and administered together. The present invention also provides a third agent that can be used in combination with a therapeutic agent for movement disorders that acts as a non-competitive NMDA receptor blocker or ion channel blocker to increase the efficacy of the primary therapeutic agent. . A particularly preferred ion channel blocker is magnesium. Alternatively, magnesium can be administered alone for the prevention and treatment of movement disorders. |